Open-label, prospective evaluation of adalimumab for psoriasis patients who were nonresponders to etanercept

被引：0
|
作者：
Martyn-Simmons, C. [1 ]
Green, E. [1 ]
Ash, G. [1 ]
Groves, R. [1 ]
Smith, C. H. [1 ]
Barker, J. N. W. N. [1 ]
机构：
[1] St Johns Inst Dermatol, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2008年 / 159卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：2
相关论文
共 50 条
  • [21] Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study
    Morita, Akimichi
    Yamazaki, Fumikazu
    Matsuyama, Takashi
    Takahashi, Kenzo
    Arai, Satoru
    Asahina, Akihiko
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Hasegawa, Yuichi
    Williams, David
    Matsuda, Naoto
    Kitamura, Susumu
    JOURNAL OF DERMATOLOGY, 2018, 45 (12): : 1371 - 1380
  • [22] A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
    Moore, Angela
    Gordon, Kenneth B.
    Kang, Sewon
    Gottlieb, Alice
    Freundlich, Bruce
    Xia, Amy
    Stevens, Seth R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) : 598 - 603
  • [23] Open-label prospective clinical evaluation of Tegretrol XR in patients with epilepsy
    Tikku, D
    Sachdeo, RC
    Kaufman, KR
    EPILEPSIA, 1999, 40 : 68 - 69
  • [24] Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study
    Papoutsaki, M.
    Chimenti, M. S.
    Talamonti, M.
    Zangrilli, A.
    Teoli, M.
    Kroegler, B.
    Perricone, R.
    Chimenti, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (06) : 1414 - 1414
  • [25] Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics
    Papoutsaki, Marina
    Chimenti, Maria-Sole
    Costanzo, Antonio
    Talamonti, Marina
    Zangrilli, Arianna
    Giunta, Alessandro
    Bianchi, Luca
    Chimenti, Sergio
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (02) : 269 - 275
  • [26] Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
    Suhler, Eric B.
    Lowder, Careen Y.
    Goldstein, Debra A.
    Giles, Tracy
    Lauer, Andreas K.
    Kurz, Paul A.
    Pasadhika, Sirichai
    Lee, Shelly T.
    de Saint Sardos, Alexandre
    Butler, Nicholas J.
    Tessler, Howard H.
    Smith, Justine R.
    Rosenbaum, James T.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (04) : 481 - 486
  • [27] Infliximab for severe, treatment resistant psoriasis: a prospective, open-label study
    Smith, CH
    Jackson, K
    Bashir, S
    Chew, A
    Powell, A
    Perez, A
    Wain, M
    Barker, JNWN
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01)
  • [28] Adalimumab is effective in patients with fistulizing Crohn's disease who were primary nonresponders to infliximab treatment
    Lichtiger, Simon
    Binion, David
    Wolf, Douglas
    Present, Daniel
    Lomax, Kathleen
    Rafiq, Shuvobrata
    Holdbrook, Fred
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S416 - S416
  • [29] Clinically important nail psoriasis improvements are achieved with adalimumab (HUMIRA®):: results from a large open-label prospective study (STEREO)
    van den Bosch, F.
    Reece, R.
    Behrens, F.
    Wendling, D.
    Mikkelsen, K.
    Frank, M.
    Kron, M.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 421 - 421
  • [30] Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan
    Wu, Yi-Fang
    Shin, Yi-Chin
    Yang, Chih-Hsun
    Huang, Yu-Huei
    DERMATOLOGICA SINICA, 2013, 31 (02) : 49 - 53
12345